Dr. Reddy has recorded an exciting 104% growth in sales and a 420% growth in profit before tax for 2QFY02. Operating margins have leapfrogged to 49.4% in the concerned quarter from 25.9% last year. The performance of the company is much above market expectations. The figures for the current quarter is on a consolidated basis with Cheminor drugs and American Remedies. To provide meaningful comparison, previous quarter numbers are also on a consolidated basis. The surge in revenues and profits was mainly fuelled by generic fluoxetine and other export formulations.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Tax Provision/(Deferred benefit) net
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Fully Diluted Earnings per share*
P/E (at current price)
The current quarter witnessed a marked shift in the business mix of the company. Generics business which started with modest sales in 1QFY02 contributed more than 39% of the total turnover. This was mainly fuelled by fluoxetine 40 mg capsules contributing around 35% to the total turnover of the company i.e Rs 1,639 m (US$ 35 m). It may be recalled that Dr. Reddy's received a para IV certifications (which entitles the company to have 180 days generic marketing exclusivity) for fluoxetine in last quarter. The current quarter seems to reflect 60 days (of the 180 days exclusivity) of generic fluoxetine sales. The 180-day marketing exclusivity for Fluoxetine runs between August 2001 and February 2002. The conversion rate for fluoxetine i.e. switch from branded Prozac has been on a steep rise in the last two months and currently stands at around 80%. i.e. 80% of total prescribed sales of the drug in the US is marketed by Dr. Reddy's. The company has recently also received final approval for marketing famotidine and Enalapril tablets in the US. Dr. Reddy's now has a total of 14 ANDA filings including 5 Para IV certifications.
The company also received Rs 236 m (US$ 5 m) from Novartis as upfront payment for the licensing of its diabetic molecule which has been included in the sales revenues.Excluding one time receipt for upfront payment and sales of fluoxetine, revenues have jumped 26%. Domestic formulations sales grew by 7% more or less in line with domestic pharma market growth.
Dr. Reddy's is currently trading at Rs 1,115 on 1HFY02 annualised earnings multiple of 21x. It may be noted however, that the sales of fluoxetine for last two months should not be taken as indicative of next four months exclusivity sales. The sales of the drug are through the company's marketing tie-up with Par Laboratories. It may be the case that Par Laboratories may have stocked up the drug in anticipation of sales. We would be revising our earnings estimates shortly inview of milestone payment receipt and bigger breakthrough in the generics market.
The company has also declared a special interim dividend of 100% I.e. Rs 5 per share.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407